- |||||||||| cinacalcet HCl / Generic mfg.
Management Strategies for Hypercalcemia in Breast Cancer with Bone Metastases: A Focus on Glucocorticoids and Cinacalcet (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1553;
This case demonstrates the unusual occurrence of elevated 1,25-dihydroxyvitamin D in the setting of solid tumor, thereby suggesting the utility of glucocorticoids as a treatment option for HCM resistant to usual therapy. It also shows the effectiveness of cinacalcet in managing non-PTH-mediated HCM, which possibly works via increased renal clearance of calcium and could be used as an additional effective therapeutic option in these patients.
- |||||||||| Prolia (denosumab) / Amgen
PTH-independent Hypercalcemia Secondary to Severe Tophaceous Gout Bone Erosion (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1549;
In this case hypercalcemia appeared due to severe gouty arthropathy that resolved after treatment with uricase. It is likely that inflammation and granulomatous changes at the tophus-bone interface stimulated osteoclast activity and calcitriol production resulting in hypercalcemia.
- |||||||||| Prolia (denosumab) / Amgen
Recurrent hyperparathyroidism due to parathyromatosis (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1533;
Due to the scarcity of cases, there are no well-defined clinical guidelines for diagnosis and management. While a great tool, Sestamibi scans in his case have been negative or not completely inclusive of foci that were later found in surgical pathology.
- |||||||||| Prolia (denosumab) / Amgen
A "PTH-mediated" Hypercalcemia of Malignancy (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1528;
During the previous hospitalization, her admission calcium was 17 mg/dL and was treated with IV fluids, calcitonin, and zoledronic acid...The patient was managed as per hypercalcemia of malignancy guidelines with IV fluids and denosumab... This is a rare case of endometrial cancer with liver metastasis and ectopic PTH secretion by primary tumor leading to recurrent hospitalizations related to hypercalcemia.
- |||||||||| Prolia (denosumab) / Amgen
PTH-independent, Calcitriol-mediated hypercalcemia in Renal cell carcinoma (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_541;
Usually, the etiology for hypercalcemia in patients with renal cell carcinoma is the overproduction of PTHrP, which was not the case with our patient. The ultimate resolution of hypercalcemia of malignancy was attained by treating the underlying malignancy.
- |||||||||| Prolia (denosumab) / Amgen, Erleada (apalutamide) / J&J
A Case of Tumour-induced Osteomalacia Which Remitted After Treatment of Metastatic Prostate Cancer. (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_525;
SC denosumab 60mg Q6monthly was also commenced in view of extensive bone metastases...Despite metastatic disease, this patient responded exceedingly well to his cancer therapy. Suppression of the tumour cells with androgen deprivation therapy resulted in the lack of phosphotonin production and remission of his TIO.
- |||||||||| Arexvy (respiratory syncytial virus vaccine, adjuvanted) / GSK
Journal: Adjuvanted Vaccine to Prevent Respiratory Syncytial Virus in Adults Ages 60 Years and Older. (Pubmed Central) - May 4, 2024
The vaccine was generally well tolerated in clinical trials, with the most frequently observed and reported adverse events being mild to moderate injection site pain, fatigue, myalgia, headache, and arthralgia. This article includes a description of Arexvy, the target population, contraindications, side effects, and clinical implications when considering the use of this vaccine.
- |||||||||| Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
Enrollment closed, Trial completion date: HVRRICANE: Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth (clinicaltrials.gov) - May 3, 2024
P1, N=25, Active, not recruiting,
This article includes a description of Arexvy, the target population, contraindications, side effects, and clinical implications when considering the use of this vaccine. Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Feb 2025
- |||||||||| Toctino (alitretinoin) / Basilea
Review, Journal: Topical and Systemic Retinoids in the Management of Hidradenitis Suppurativa: A Comprehensive Literature Review. (Pubmed Central) - May 3, 2024
Although the current American and European guidelines offer different recommendations on the use of retinoids in HS, retinoids remain a valuable ally in HS management. This review provides a comprehensive analysis of the current scientific literature on retinoid therapy (topical and systemic) in HS, highlighting disparities in mechanisms of action, efficacy, and safety to clarify their role in HS treatment.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Retrospective data, Journal: Sequential administration of peripheral nerve blocks and (Pubmed Central) - May 3, 2024
In this retrospective chart review, there was no significant difference in adverse events or therapy discontinuation between patients receiving sequential peripheral nerve block(s) and onabotulinumtoxinA injections versus those receiving either peripheral nerve block(s) or onabotulinumtoxinA injections alone. As a result, we concluded that the combination procedure is likely safe and well tolerated in routine clinical practice.
- |||||||||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche, Livtencity (maribavir) / Takeda, GSK
Clinical, Review, Journal: Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. (Pubmed Central) - May 3, 2024
Prophylaxis with antiviral medications reduces CMV disease and CMV-associated death, compared with placebo or no treatment, in solid organ transplant recipients. These data support the continued routine use of antiviral prophylaxis in CMV-positive recipients and CMV-negative recipients of CMV-positive organ transplants.
- |||||||||| Leukeran (chlorambucil) / GSK
Journal, Lipid Nanoparticle: Delivery of Chlorambucil to the Brain Using Surface Modified Solid Lipid Nanoparticles. (Pubmed Central) - May 3, 2024
The in vivo biodistribution and brain uptake in C57BL6 mice and SPECT/CT imaging in Wistar rats investigated using 99mTc-labeled SLN and autoradiography suggest that the SLNs have an increasing brain uptake. We have demonstrated the delivery of the anticancer drug chlorambucil (CLB) to glioma.
- |||||||||| zamaporvint (RXC004) / Redx
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: PORCUPINE: A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) (clinicaltrials.gov) - May 3, 2024
P2, N=25, Completed,
We have demonstrated the delivery of the anticancer drug chlorambucil (CLB) to glioma. Recruiting --> Completed | N=50 --> 25 | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Aug 2023 --> Apr 2024
- |||||||||| Brexafemme (ibrexafungerp) / SCYNEXIS, GSK
Preclinical, Journal, Monotherapy: Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. (Pubmed Central) - May 2, 2024
Monotherapies also reduce the lung and brain fungal burden by ~0.5-1.0log10 conidial equivalents (CE)/g of tissue vs placebo in mice infected with R. delemar (P < 0.05), while a combination of ibrexafungerp plus LAMB lowered the fungal burden by ~0.5-1.5log10 CE/g compared to placebo or any of the monotherapy groups (P < 0.03). These results are promising and warrant continued investigation of ibrexafungerp as a novel treatment option against mucormycosis.
- |||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Journal: 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. (Pubmed Central) - May 2, 2024
3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP. (Pubmed Central) - May 2, 2024
The response to a biologic treatment for CRSwNP control may be heterogenous and it seems that patients may benefit from switching improving control in equal measure in the upper and lower airway. Further studies to explore the endotype/phenotype which best fits with each biologic are mandatory to personalize the therapy.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Botulinum Toxin Injections for Hyperhidrosis () - May 2, 2024 - Abstract #INDERCOS2024INDERCOS_160;
This presentation aims to offer insights into the commercially available botulinum toxin formulations and their utility in addressing primary hyperhidrosis. Treatment procedures and techniques, efficacy, duration of effect, safety profile, cost considerations, comparison with other treatments, and future directions will be discussed.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Xolair (omalizumab) / Roche, Novartis
Serendipity in dermatology () - May 2, 2024 - Abstract #INDERCOS2024INDERCOS_8;
Serendipity due omalizumab: also useful for treating pemphigus? It needs more studies (12).
- |||||||||| Mosquirix (RTS,S) / GSK
Journal: Malaria vaccines: a new tool for elimination? (Pubmed Central) - May 2, 2024
In October 2023, a second vaccine received WHO approval for deployment in the same population, following demonstration of around 70 % efficacy in protecting young children against malaria for one year. Given their partial efficacy, however, these vaccines are not generally recommended for travelers to endemic countries.
- |||||||||| bepirovirsen (GSK3228836) / GSK
Journal: Advances in the Pharmacological Management of Chronic Hepatitis B. (Pubmed Central) - May 1, 2024
Eradication of HBV infection with currently available therapies is not yet possible. Experts are developing innovative treatments, such as bepirovirsen, to achieve functional cure for this disease and to reduce morbidity and mortality associated with hepatic cirrhosis and hepatocellular carcinoma.
- |||||||||| Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Journal: Daprodustat and Heart Failure in CKD. (Pubmed Central) - May 1, 2024
A greater number of first heart failure hospitalization events occurred in patients treated with daprodustat compared with conventional ESA, but this difference did not reach statistical significance. Differences in the number of heart failure hospitalization events were most apparent in patients not receiving dialysis and in patients with history of heart failure.
- |||||||||| sulopenem etzadroxil/probenecid (CP-70429) / Iterum, Orapenem (tebipenem pivoxil) / Meiji Seika, GSK
Journal: A pairwise approach to revitalize ?-lactams for the treatment of TB. (Pubmed Central) - May 1, 2024
Through a comprehensive screen of oral ?-lactam pairs, we have discovered that cefuroxime strongly potentiates the bactericidal activity of tebipenem and sulopenem-advanced clinical candidates-and amoxicillin, at concentrations achieved clinically. ?-lactam pairs thus have the potential to reduce TB treatment duration.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, methionine enkephalin (STAT-401) / Immune Therap, Statera BioPharma
Journal: Pre-proenkephalin 1 is Downregulated Under Unloading and is Involved in Osteoblast Biology. (Pubmed Central) - Apr 30, 2024
Interestingly, primary osteoblasts isolated from Penk1-/- mice showed lower metabolic activity, ALP activity, and nodule mineralization, as well as a lower number of CFU-F compared to osteoblasts isolated from WT mice, suggesting that, unlike the transient inhibition, the chronic Penk1 deletion affects both osteoblast differentiation and activity. Taken together, these results highlight a role for Penk1 in the regulation of the response of the bone to mechanical unloading, potentially acting on osteoblast differentiation and activity in a cell-autonomous manner.
|
